Cosmo Pharmaceuticals Highlights Study Published in "The Lancet" Demonstrating the Efficacy of GI Genius(TM) in Colonoscopy Procedures
Dublin, Ireland--(Newsfile Corp. - September 2, 2024) - Cosmo Intelligent Medical Devices (Cosmo IMD), a division of Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”), the developer and manufacturer of the GI Genius™ intelligent endoscopy system, is pleased to announce the publication of a landmark study in “The Lancet”. This study, titled “Polyp detection with colonoscopy assisted by the GI Genius™ artificial intelligence endoscopy module compared with standard colonoscopy in...
2024-09-02 1:08 AM EDT
Cosmo Intelligent Medical Devices Unveils Next Generation GI Genius(TM) Hardware with New FDA Clearance
Dublin, Ireland--(Newsfile Corp. - July 31, 2024) - Cosmo Intelligent Medical Devices (Cosmo IMD), a division of Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) focused on pioneering medical devices powered by Artificial Intelligence, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the next generation GI Genius™ hardware, the latest development of the GI Genius™ intelligent endoscopy system, which Medtronic exclusively distributes...
2024-07-31 1:55 AM EDT
Cosmo Achieves Robust Financial Performance in H1 2024 and Confirms Its Full Year Guidance
Dublin, Ireland--(Newsfile Corp. - July 24, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced its 2024 half year results. Key highlights Health Tech: Upfront payment of $100 million received from Medtronic related to expansion of AI-driven partnership; Cosmo expects to receive an additional $100m from Medtronic this year linked to new services and the delivery of additional AI products/features which will further improve colonoscopy procedure quality measures...
2024-07-24 1:10 AM EDT
Invitation to Cosmo's Half-Year 2024 Webcast on 24 July 2024
Dublin, Ireland--(Newsfile Corp. - July 9, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced today that it will publish its Half-Year 2024 results on Wednesday, 24 July 2024 at 07:00 am CEST. Cosmo invites investors, financial analysts and business/life science journalists to a live video webcast presentation at 2:00 pm CEST to discuss the financial and operating results as well as the next milestones of the Company. The presentation includes a Q&A session and is...
2024-07-09 1:05 AM EDT
Cosmo Shareholders Approved All Resolutions Proposed by the Board of Directors at Extraordinary General Meeting
Dublin, Ireland--(Newsfile Corp. - July 5, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) shareholders today approved all resolutions proposed by the Board of Directors at an Extraordinary General Meeting of the Company. A total of 7,173,931 ordinary shares of the share capital of Cosmo were represented at this general meeting of shareholder
2024-07-05 10:25 AM EDT
Cosmo's Oral Diagnostic Drug Lumeblue(R) Receives Approval of New Drug Application in China
Dublin, Ireland--(Newsfile Corp. - June 18, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) reported that its partner and exclusive licensee of Lumeblue® (Methylene Blue MMX®) for China, China Medical System Holdings Limited (“CMS”) (SEHK: 867), has received the approval for the innovative product in the territory by the National Medical Products Administration of China (NMPA) on 11 June. Today, on 18 June, CMS also obtained the corresponding Drug Registration Certificate....
2024-06-18 12:13 PM EDT
Cosmo to Bring Real-Time AI into Intelligent Medical Devices with NVIDIA IGX
Dublin, Ireland--(Newsfile Corp. - June 3, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) with its Cosmo Intelligent Medical Devices division (“Cosmo IMD”) is consolidating its strategy to accelerate the adoption of responsible and regulated AI in healthcare, obtaining pragmatic results in its mission to address unmet clinical needs and improve patient outcomes. GI Genius™ has been conceived and is being designed, developed, manufactured by Cosmo IMD, and distributed by...
2024-06-03 1:02 AM EDT
Cosmo Reports Excellent Final Full Year 2023 Financial Results - Increases Operating Profit Guidance for 2024 - Dividend of 2.00 per Share Will Be Proposed at EGM on 5 July 2024
Dublin, Ireland--(Newsfile Corp. - May 31, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced its final audited results for the financial year 2023. Financial highlights As previously announced when publishing preliminary unaudited 2023 figures on 20 March 2024, Cosmo delivered strong growth across its core business in 2023. The core business performed follows in 2023: Revenues € 92.8 million EBITDA of € 20.4 million Operating profit € 6.1 million Profit...
2024-05-31 6:09 PM EDT
Cosmo Pharmaceuticals' Shareholders Approve All Agenda Items at Annual General Meeting
Dublin, Ireland--(Newsfile Corp. - May 24, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced that its shareholders approved all agenda items at today's annual general meeting of shareholders. A total of 7,417,916 ordinary shares in the share capital of Cosmo were represented at this annual general meeting of shareholders constituting 42.28% of the total outstanding ordinary shares in the share capital of Cosmo (as of the record date). Shareholders elected (or...
2024-05-24 5:36 PM EDT
Cosmo Has Received Approval of an Extension in Respect of the Publication and the Filing of Its Annual Report 2023
Dublin, Ireland--(Newsfile Corp. - April 29, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced that the company has been granted extension until 31 May 2024 to publish its 2023 annual report and to file such report with SIX Exchange Regulation AG. Paragraph I. of the decision of SIX Exchange Regulation AG which was received on 25 April 2024 states the following: The exemption request of COSMO (Issuer) dated 23 April 2024 regarding an extension of the deadline...
2024-04-29 5:12 PM EDT
Cosmo Announces Leadership Changes
Dublin, Ireland--(Newsfile Corp. - April 25, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced the appointment of Giovanni Di Napoli as its new Chief Executive Officer, along with changes to its Board of Directors, at the upcoming Annual Gene
2024-04-25 1:32 AM EDT
Cosmo and Medtronic Unveil the Future of AI in GI: Genius Summit 2024 Reveals Innovations and Collaborations That Advance Endoscopic Care
Dublin, Ireland--(Newsfile Corp. - April 12, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announces that Medtronic plc (NYSE: MDT), a global leader in healthcare technology, presented at the Genius Summit 2024 the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system developed by Cosmo IMD, along with a new strategic collaboration designed to enhance...
2024-04-12 1:17 AM EDT
Cosmo Reports Excellent Preliminary Unaudited Full Year 2023 Core Financial Results - Record Guidance for 2024 - Doubles Dividend to 2.00 per Share
Dublin, Ireland--(Newsfile Corp. - March 20, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced its preliminary unaudited results for the financial year 2023. Financial highlights Cosmo delivered strong growth across its core business in 2023. The company continues to make excellent progress on execution of its strategy with the a
2024-03-20 3:18 AM EDT
Cosmo Pharmaceuticals Announces Approval of Winlevi(R) in Australia
Dublin, Ireland--(Newsfile Corp. - March 19, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) reported today that its partner Sun Pharmaceutical Industries Limited (Reuters: SUN.BO) (Bloomberg: SUNP IN), (NSE: SUNPHARMA) (BSE: 524715) (“Sun Pharma”) has announced that the Australian Therapeutic Goods Administration (TGA) has granted regulatory approval for Winlevi® (clascoterone cream 1%). Winlevi® is indicated for the topical treatment of acne vulgaris in patients 12 years...
2024-03-19 2:40 AM EDT
Invitation to Cosmo's Investor Day and Full-Year 2023 Webcast - Zurich, 20 March 2024
Dublin, Ireland--(Newsfile Corp. - January 25, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced today that it will publish its Full-Year 2023 results on Wednesday, 20 March 2024 at 7:00 am CET. FY 2023 Results Webcast Cosmo invites investors, financial analysts and business/life sciences journalists to a live video webcast presentation which will follow at 11:00 am CET with Mauro Ajani, Chairman, and Alessandro Della Chà, CEO, to discuss the financial and...
2024-01-25 1:30 AM EST
Cosmo Pharmaceuticals and Medtronic Forge Ahead in AI-Driven Care
Dublin, Ireland--(Newsfile Corp. - December 11, 2023) - Cosmo Pharmaceuticals (SIX: COPN) (XETRA: C43) (“Cosmo”) announces that its subsidiary Cosmo Intelligent Medical Devices has entered into a definitive agreement to expand its partnership with Medtronic plc (NYSE: MDT), a global leader in healthcare technology. This AI-driven partnership will further capitalize on the achievements already realized with the GI Genius™ intelligent endoscopy module, offering continued innovation and scalable...
2023-12-11 2:02 AM EST